Jan 18 2012
US BioDesign announced today the launch of its cardiovascular biomaterials business segment. This portion of US BioDesign will be responsible for the research, analysis and production of products and services in the cardiovascular device area. This includes OEM components for all cardiovascular products, including cardiac and peripheral stents, vascular grafts and stent grafts, vascular access devices, pacemakers, and accessory products for heart valves.
The U.S. cardiovascular device market was $8.29 billion in 2007 and is expected to reach $20.70 billion by 2014, which represents a Compound Annual Growth Rate (CAGR) of 14.5% from 2009 to 2014. The U.S. cardiovascular biomaterial market was $3.43 billion in 2007 and is expected to reach $7.74 billion in 2014 with a CAGR of 13% from 2009 to 2014.
US BioDesign is well situated to take full advantage of these rapidly growing markets as a result of the world class research and development expertise of its team and its ability to solve customers' problems as biomedical engineers, not textile engineers. US BioDesign's focus on the right medical construct solution for its customers' problems has resulted in a significant decrease in its delivery timelines, which in turn has allowed customers to utilize US BioDesign's components into their devices, quickly and efficiently, thus shortening the overall development timelines.
"Time is money for our customers," says US BioDesign CEO, Tom Molz. "US BioDesign's mission is to be the most effective OEM supplier of biomedical textile structures in the industry and I am very pleased that we are having quite a bit of initial success, especially in the cardiovascular area," he added.
Feeling lonely? It may affect how your brain reacts to food, new research suggests